Specifications
Properties
Additional Info
Background
Specifications
| SPECIES REACTIVITY: | Human, Mouse, Rat |
|---|---|
| TESTED APPLICATIONS: | ELISA, WB |
| APPLICATIONS: | BCL6 antibody can be used for detection of BCL6 by Western blot at 1 μg/mL. Antibody validated: Western Blot in rat samples. All other applications and species not yet tested. |
| USER NOTE: | Optimal dilutions for each application to be determined by the researcher. |
| POSITIVE CONTROL: | 1) Cat. No. 1462 - Rat Lung Tissue Lysate |
| PREDICTED MOLECULAR WEIGHT: | 78 kDa |
| SPECIFICITY: | Three alternatively spliced transcript variants have been observed |
| IMMUNOGEN: | BCL6 antibody was raised against an 18 amino acid synthetic peptide near the center of human BCL6. The immunogen is located within amino acids 370 - 420 of BCL6. |
| HOST SPECIES: | Rabbit |
Properties
| PURIFICATION: | BCL6 Antibody is affinity chromatography purified via peptide column. |
|---|---|
| PHYSICAL STATE: | Liquid |
| BUFFER: | BCL6 Antibody is supplied in PBS containing 0.02% sodium azide. |
| CONCENTRATION: | 1 mg/mL |
| STORAGE CONDITIONS: | BCL6 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| CLONALITY: | Polyclonal |
| ISOTYPE: | IgG |
| CONJUGATE: | Unconjugated |
Additional Info
| ALTERNATE NAMES: | BCL6 Antibody: BCL5, LAZ3, BCL6A, ZNF51, ZBTB27, BCL5, B-cell lymphoma 6 protein, B-cell lymphoma 5 protein, BCL-6 |
|---|---|
| ACCESSION NO.: | NP_001124317 |
| PROTEIN GI NO.: | 195927002 |
| OFFICIAL SYMBOL: | BCL6 |
| GENE ID: | 604 |
Background
| BACKGROUND: | BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML). |
|---|---|
| REFERENCES: | 1) Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 1995; 14:6209-17. | 2) Dent AL, Shaffer AL, Yu X, et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science1997; 276:589-92. | 3) Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 1997; 16:161-70. | 4) Hurtz C, Hatzi K, Cerchietti L, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 2011; 208:2163-74. |
For Research Use Only
